The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Open accessAbstract
BACKGROUND: Drugs that selectively inhibit serotonin reuptake are effective treatments for adults with mood and anxiety disorders, but limited data are available on the safety and efficacy of serotonin-reuptake inhibitors in children with anxiety disorders. METHODS: We studied 128 children who were 6 to 17 years of age; who met the criteria for social phobia, separation anxiety disorder, or generalized anxiety disorder; and who had received psychological treatment for three weeks without improvement. The children were randomly assigned to receive fluvoxamine (at a maximum of 300 mg per day) or placebo for eight weeks and were evaluated with rating scales designed to assess the degree of anxiety and impairment. RESULTS: Children in the fluvoxamine group had a mean (+/-SD) decrease of 9.7+/-6.9 points in symptoms of anxiety on the Pediatric Anxiety Rating Scale (range of possible scores, 0 to 25, with higher scores indicating greater anxiety), as compared with a decrease of 3.1+/-4.8 points among children in the placebo group (P<0.001). On the Clinical Global Impressions-Improvement scale, 48 of 63 children in the fluvoxamine group (76 percent) responded to the treatment, as indicated by a score of less than 4, as compared with 19 of 65 children in the placebo group (29 percent, P<0.001). Five children in the fluvoxamine group (8 percent) discontinued treatment because of adverse events, as compared with one child in the placebo group (2 percent). CONCLUSIONS: Fluvoxamine is an effective treatment for children and adolescents with social phobia, separation anxiety disorder, or generalized anxiety disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Despite its positive effects, the use of paroxetine may have caused as side-effects insomnia, decreased appetite, vomiting, withdrawal, agitation, emotional liability and four patients described suicide ideations without attempting to consummate.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [41]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, fluvoxamine is considered effective and well tolerated in the long-term treatment of anxiety disorders with children and adolescents [40].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the fluvoxamine condition drop-out was higher (n = 5) than the placebo group (n = 2) due to sideeffects.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, studies examining the efficacy of fluvoxamine and sertraline have reported a significant reduction in the severity of the anxiety symptoms after only 12 weeks [37,59].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additional research suggests that combining psychotherapy with pharmacotherapy yields better outcomes than either approach alone, as psychotherapy can teach valuable skills in managing fear-inducing social situations while pharmacotherapy alleviates symptoms facilitating greater participation in behavioral interventions [60,61].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [60]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another study found that 76% of participants treated with fluvoxamine were classified as 'much improved,' compared to 29% in the placebo group [59].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The participants allocated to the fluvoxamine experimental group benefited from a significant decrease in anxiety symptoms compared to the participants allocated to the placebo group.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“The most prevalent observed side-effects were headache, abdominal discomfort, increased motor activity and difficulty falling asleep.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
BIRMAHER, B., KHETARPAL, S., BRENT, D., CULLY, M., BALACH, L., KAUFMAN, J., & NEER, S. M. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199704000-00018 · Cited by 2,846
The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity
MARCH, J. S., PARKER, J. D. A., SULLIVAN, K., STALLINGS, P., & CONNERS, C. K. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199704000-00019 · Cited by 2,236
Self-citationPine, D. S., Cohen, P., Gurley, D., Brook, J., & Ma, Y. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.1.56 · Cited by 1,753
Self-citationSHAFFER, D., FISHER, P., DULCAN, M. K., DAVIES, M., PIACENTINI, J., SCHWAB-STONE, M. E., LAHEY, B. B., BOURDON, K., JENSEN, P. S., BIRD, H. R., et al. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199607000-00012 · Cited by 1,587
Self-citationUsers' Guides to the Medical Literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.21.2598 · Cited by 1,185
Emslie, G. J. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230069010 · Cited by 971
Research works printed but not linked: 3
- Greenhill LL, 1998, Psychopharmacol Bull, 34, 155
- Walkup J, Davies M. The Pediatric Anxiety Rating Scale (PARS): a reliability study. In: Scientific proceedings of the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, October 19–24, 1999:NR78. abstract.
- Wagner KD, Birmaher B, Carlson G, et al. Multi-center trial of paroxetine and imipramine in the treatment of adolescent depression. In: Scientific proceedings of the 45th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, Calif., October 27–November 1, 1998:S12D. abstract.
Cited by
Sorted by citations
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Self-citationStein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 884
Metadata
- Authors
- Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., Klee, B., McCracken, J., Bergman, L., Piacentini, J., March, J., Compton, S., Robinson, J., O'Hara, T., Baker, S., Vitiello, B., Ritz, L., & Roper, M.
- Affiliations
- New York State Psychiatric Institute (US)
- University of California, Los Angeles (US)
- Duke University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-04-26
- Volume
- 344
- Issue
- 17
- Pages
- 1279-1285
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2330595721
- Cited by
- 588
- References
- 42
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 18 · 2023: 7 · 2022: 12 · 2021: 14 · 2020: 12 · 2019: 15 · 2018: 10 · 2017: 18 · 2016: 17 · 2015: 19 · 2014: 20 · 2013: 23 · 2012: 23
- FWCI
- 73.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Brown University
- Johns Hopkins University
- York University
- National Institutes of Health (n01mh060005-010, n01mh060016-007, n01mh070010-001)
- University of Illinois at Urbana-Champaign
- National Institute of Mental Health (N01 MH 70010, N01 MH60005, N01MH60016)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- fluvoxamine, selective serotonin reuptake inhibitors, childhood anxiety disorders, social anxiety disorder, separation anxiety disorder, generalized anxiety disorder, children and adolescents, drug safety and efficacy, adverse events
- MeSH terms
- Adolescent, Anxiety Disorders, Anxiety, Separation, Child, Female, Humans, Male, Phobic Disorders, Psychotherapy, Anti-Anxiety Agents, Fluvoxamine, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
